Active, not recruitingPhase 2NCT03383094
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Loren Mell, MD
- Principal Investigator
- Loren Mell, MDUniversity of California, San Diego
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 126 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2027
Study locations (6)
- University of Arizona Cancer Center, Tucson, Arizona, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- H. Lee Moffitt Cancer Center & Research Facility, Tampa, Florida, United States
- Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri, United States
- University of Cincinnati Medical Center, Cincinnati, Ohio, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03383094 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC
See all trials for Autosomal dominant multiple pterygium syndrome →